Peptide | Sequence | Binding capability (%)* |
---|
| | HLA-A2 | HLA-A24 |
---|
9-mer | QIFNKPYWL | 66.8 | 40.3 |
10-mer | AQIFNKPYWL | 74.9 | 51.7 |
Flu M1 | GILGFVFTL | 116.7 | ND |
EBV | TYGPVFMCL | ND | 170.6 |
K-Ras | KLVVVG AGGV | 3.3 | 3.8 |
- *HLA-A2 or HLA-A24-binding capability was estimated by increase in mean fluorescence intensity (MFI), determined by flowcytometry after staining of RMA-S/A2 or RMA-S/A24 cells with anti-HLA-A2 or anti-HLA-A24 mAb, as follows; MFI increase (%) = (MFI with a given peptide – MFI without peptide)/(MFI without peptide) X 100. As positive controls, an HLA-A2-binding peptide derived from influenza virus M1 (Flu M1) or an HLA-A24-binding peptide derived from Epstein-Barr virus LMP2 (EBV) was used. As a negative control, a peptide derived from oncogene K-ras was used. ND, not determined.